Workflow
以创新药研发进展为核心考核指标 前沿生物通过股权激励助力战略落地

Core Viewpoint - Frontier Biotech (688221) has announced a restricted stock incentive plan for 2025, aiming to attract and retain talent while enhancing the company's core competitiveness and achieving strategic goals [1] Group 1: Incentive Plan Details - The plan includes granting a total of 5 million restricted stocks, with 4.25 million for initial grants and 750,000 reserved, at a price of 8.56 yuan per share [1] - The initial grant will be distributed among 27 employees, representing 8.94% of the total workforce of 302 as of December 31, 2024 [2] - 16 out of the 27 recipients are assessed based on R&D metrics, receiving 3.07 million shares, which accounts for 61.40% of the total shares granted [2] Group 2: Performance Targets - For the first vesting period in 2025, the company must achieve at least one IND application and eight new drug patent applications to meet the 100% vesting requirement [2] - For the second vesting period in 2026, the cumulative targets include five IND applications and 16 new drug patent applications, along with one BD transaction for small nucleic acid drugs [3] - Revenue growth targets are set at a minimum of 10% for 2025 and a cumulative growth of 30% for 2025-2026, based on 2024 revenue [3] Group 3: Focus on Small Nucleic Acid Drugs - The incentive plan emphasizes achieving BD transactions for small nucleic acid drugs, highlighting the company's focus in this area [4] - Frontier Biotech has developed a comprehensive and high-standard development system for small nucleic acid drugs, leveraging internal and external collaborations [4] - The company is advancing multiple drug candidates in various therapeutic areas, including IgA nephropathy and metabolic diseases, all currently in preclinical stages [4] Group 4: Technological Innovations - The company has developed a proprietary siRNA delivery vehicle, ACORDE, which is currently under international patent application [5] - The strategic focus is on innovative drug development and commercialization, marking a critical phase for high-quality business growth [5] - The performance metrics of the incentive plan align with the company's strategic needs and are designed to enhance competitiveness and employee motivation [5]